$3.29
-0.04-1.20%
At close: -
$3.29
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Relay Therapeutics Analyst Ratings and Price Targets | NASDAQ:RLAY | Benzinga
Relay Therapeutics Inc has a consensus price target of $18.82 based on the ratings of 12 analysts. The high is $29 issued by Raymond James on April 19, 2023. The low is $4 issued by Wells Fargo on April 17, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, HC Wainwright & Co., and Goldman Sachs on April 17, 2025, March 7, 2025, and February 27, 2025, respectively. With an average price target of $12.67 between Wells Fargo, HC Wainwright & Co., and Goldman Sachs, there's an implied 285.01% upside for Relay Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
HC Wainwright & Co.
Goldman Sachs
Stifel
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Relay Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | 21.58% | Wells Fargo | — | → $4 | Initiates | → Equal-Weight | Get Alert |
| 03/07/2025 | Buy Now | 386.32% | HC Wainwright & Co. | Robert Burns43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 447.11% | Goldman Sachs | Salveen Richter51% | $20 → $18 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | 599.09% | Stifel | Bradley Canino40% | $27 → $23 | Maintains | Buy | Get Alert |
| 01/14/2025 | Buy Now | 386.32% | HC Wainwright & Co. | Robert Burns43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 538.3% | JMP Securities | Silvan Tuerkcan46% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | 447.11% | Leerink Partners | Christopher Liu51% | $19 → $18 | Maintains | Outperform | Get Alert |
| 12/04/2024 | Buy Now | 386.32% | HC Wainwright & Co. | Robert Burns43% | $20 → $16 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 507.9% | HC Wainwright & Co. | Robert Burns43% | $19 → $20 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | 477.51% | HC Wainwright & Co. | Robert Burns43% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 538.3% | JMP Securities | Silvan Tuerkcan46% | $21 → $21 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 751.06% | Stifel | Bradley Canino40% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 477.51% | HC Wainwright & Co. | Robert Burns43% | $18 → $19 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 629.48% | B of A Securities | Jason Gerberry59% | $20 → $24 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | 538.3% | JP Morgan | Eric Joseph44% | $23 → $21 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 416.72% | Barclays | Peter Lawson42% | $14 → $17 | Maintains | Overweight | Get Alert |
| 09/10/2024 | Buy Now | 507.9% | Goldman Sachs | Salveen Richter51% | → $20 | Reinstates | → Buy | Get Alert |
| 09/10/2024 | Buy Now | 386.32% | Jefferies | Akash Tewari44% | $10.6 → $16 | Upgrade | Hold → Buy | Get Alert |
| 09/10/2024 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Downgrade | Outperform → Perform | Get Alert |
| 08/07/2024 | Buy Now | 599.09% | JP Morgan | Eric Joseph44% | $29 → $23 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 629.48% | Oppenheimer | Matthew Biegler37% | $25 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2024 | Buy Now | 325.53% | Barclays | Peter Lawson42% | $15 → $14 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 538.3% | JMP Securities | Silvan Tuerkcan46% | $24 → $21 | Maintains | Market Outperform | Get Alert |
| 07/17/2024 | Buy Now | 447.11% | HC Wainwright & Co. | Robert Burns43% | $20 → $18 | Maintains | Buy | Get Alert |
| 06/07/2024 | Buy Now | 507.9% | HC Wainwright & Co. | Robert Burns43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 355.93% | Barclays | Peter Lawson42% | $15 → $15 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/06/2024 | Buy Now | 629.48% | JMP Securities | Silvan Tuerkcan46% | $24 → $24 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/06/2024 | Buy Now | 659.88% | Oppenheimer | Matthew Biegler37% | $33 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 811.85% | Stifel | Bradley Canino40% | $25 → $30 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 416.72% | HC Wainwright & Co. | Robert Burns43% | $19 → $17 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 477.51% | HC Wainwright & Co. | Robert Burns43% | $33 → $19 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 903.04% | HC Wainwright & Co. | Robert Burns43% | $30 → $33 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 811.85% | HC Wainwright & Co. | Robert Burns43% | $32 → $30 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 903.04% | Oppenheimer | Matthew Biegler37% | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 06/09/2023 | Buy Now | 872.64% | HC Wainwright & Co. | Robert Burns43% | $46 → $32 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 629.48% | JMP Securities | Silvan Tuerkcan46% | $28 → $24 | Maintains | Market Outperform | Get Alert |
| 04/20/2023 | Buy Now | 279.94% | Jefferies | Akash Tewari44% | $16 → $12.5 | Upgrade | Underperform → Hold | Get Alert |
| 04/20/2023 | Buy Now | 933.43% | Stifel | Bradley Canino40% | $38 → $34 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 781.46% | JP Morgan | Eric Joseph44% | $42 → $29 | Maintains | Overweight | Get Alert |
| 04/19/2023 | Buy Now | 751.06% | JMP Securities | Silvan Tuerkcan46% | → $28 | Reiterates | → Market Outperform | Get Alert |
| 04/19/2023 | Buy Now | 781.46% | Raymond James | Dane Leone46% | → $29 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/19/2023 | Buy Now | 355.93% | Barclays | Peter Lawson42% | $23 → $15 | Maintains | Equal-Weight | Get Alert |
| 04/18/2023 | Buy Now | 903.04% | Oppenheimer | Matthew Biegler37% | → $33 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 781.46% | Raymond James | Dane Leone46% | → $29 | Initiates | → Outperform | Get Alert |
| 04/05/2023 | Buy Now | 1176.6% | JP Morgan | Eric Joseph44% | $45 → $42 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 1298.18% | HC Wainwright & Co. | Robert Burns43% | $43 → $46 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 903.04% | Oppenheimer | Matthew Biegler37% | → $33 | Initiates | → Outperform | Get Alert |
| 01/19/2023 | Buy Now | 751.06% | JMP Securities | Silvan Tuerkcan46% | $38 → $28 | Maintains | Market Outperform | Get Alert |
| 11/07/2022 | Buy Now | 1206.99% | HC Wainwright & Co. | Robert Burns43% | $50 → $43 | Maintains | Buy | Get Alert |
| 09/30/2022 | Buy Now | 599.09% | Barclays | Peter Lawson42% | → $23 | Initiates | → Equal-Weight | Get Alert |
| 09/14/2022 | Buy Now | 1055.02% | JMP Securities | Silvan Tuerkcan46% | $35 → $38 | Maintains | Market Outperform | Get Alert |
| 09/12/2022 | Buy Now | 1419.76% | HC Wainwright & Co. | Robert Burns43% | $46 → $50 | Maintains | Buy | Get Alert |
| 09/02/2022 | Buy Now | 1115.81% | Stifel | Bradley Canino40% | → $40 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 1298.18% | HC Wainwright & Co. | Robert Burns43% | $47 → $46 | Maintains | Buy | Get Alert |
| 06/06/2022 | Buy Now | 295.14% | Jefferies | Akash Tewari44% | → $13 | Initiates | → Underperform | Get Alert |
| 05/24/2022 | Buy Now | 1176.6% | Goldman Sachs | Salveen Richter51% | $49 → $42 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 1328.57% | HC Wainwright & Co. | Robert Burns43% | $54 → $47 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 963.83% | JMP Securities | Silvan Tuerkcan46% | $50 → $35 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Relay Therapeutics (RLAY) stock?
The latest price target for Relay Therapeutics (NASDAQ:RLAY) was reported by Wells Fargo on April 17, 2025. The analyst firm set a price target for $4.00 expecting RLAY to rise to within 12 months (a possible 21.58% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
The latest analyst rating for Relay Therapeutics (NASDAQ:RLAY) was provided by Wells Fargo, and Relay Therapeutics initiated their equal-weight rating.
When was the last upgrade for Relay Therapeutics (RLAY)?
The last upgrade for Relay Therapeutics Inc happened on September 10, 2024 when Jefferies raised their price target to $16. Jefferies previously had a hold for Relay Therapeutics Inc.
When was the last downgrade for Relay Therapeutics (RLAY)?
The last downgrade for Relay Therapeutics Inc happened on September 10, 2024 when Oppenheimer changed their price target from N/A to N/A for Relay Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a initiated with a price target of $0.00 to $4.00. The current price Relay Therapeutics (RLAY) is trading at is $3.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
